Prosecution Insights
Last updated: November 20, 2026

Charanjit Aulakh, USPTO Patent Examiner

Listed by the USPTO as AULAKH, CHARANJIT

Tech Center 1600 • Art Units: 1621 1625 1629 1652

This examiner grants 81% of resolved cases

Performance Statistics

80.8%
Allow Rate
+20.8% vs TC avg
1,844
Total Applications
-14.4%
Interview Lift
755
Avg Prosecution Days
Based on 1798 resolved cases, 2023–2026

Rejection Statute Breakdown

3.4%
§101 Eligibility
20.5%
§102 Novelty
14.8%
§103 Obviousness
43.6%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17919650 TARGETING THE PALMOTYLATION/DEPALMOTYLATION CYCLE TO TREAT INFLAMMATORY DISEASES Final Rejection CORNELL UNIVERSITY
18279290 INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO Final Rejection Mindset Pharma Inc.
18279903 PROCESS FOR PREPARING A MELAMINE CONDENSATION PRODUCT Final Rejection BASF SE
18781405 METAL-ASSISTED DELAYED FLUORESCENT EMITTERS CONTAINING TRIDENTATE LIGANDS Non-Final OA ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
18790038 COMPOSITIONS AND METHODS FOR REDUCING TACTILE DYSFUNCTION, ANXIETY, AND SOCIAL IMPAIRMENT Non-Final OA President and Fellows of Harvard College
18820706 FASORACETAM CRYSTALLINE FORMS Non-Final OA THE CHILDREN'S HOSPITAL OF PHILADELPHIA
18843651 METHODS OF TREATING CANCER WITH IAP ANTAGONIST COMPOUNDS AND COMBINATION THERAPIES Non-Final OA Board of Regents, The University of Texas System
18716052 GLUCOCORTICOID RECEPTOR BLOCKADE WITH MIFEPRISTONE TO SENSITIZE PANCREATIC CANCER TO IMMUNOTHERAPY Non-Final OA BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
18839131 SMALL MOLECULES TARGETTING EIF3E TO INHIBIT TUMOR GROWTH PROGRESSION, AND METASTASIS Non-Final OA The Regents of the University of Colorado, A Body Corporate
18171735 Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer Non-Final OA ASTRAZENECA AB
18719945 AQUEOUS COSMETIC COMPOSITION COMPRISING VANILLIN OR ONE OF ITS DERIVATIVES, A SPECIFIC SEQUESTERING AGENT, AND POSSIBLY AT LEAST ONE ADDITIONAL ANTIMICROBIAL Final Rejection L'OREAL
18293923 INTEGRATED PROCESS FOR 5-(METHOXYCARBONYL)FURAN-2-CARBOXYLIC ACID (MCFC) Final Rejection Eastman Chemical Company
18504198 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE Final Rejection BRISTOL-MYERS SQUIBB COMPANY
18695585 METHOD FOR PRODUCING ALKYLFURANCARBOXYLIC ACID ESTER Non-Final OA Mitsubishi Gas Chemical Company, Inc.
18871262 BICYCLIC AMINE CDK12 INHIBITORS Non-Final OA Incyte Corporation
18939388 DERIVATIVES OF AN FGFR INHIBITOR Non-Final OA Incyte Corporation
18678931 TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS Final Rejection INCYTE CORPORATION
18792897 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES Non-Final OA UNIVERSAL DISPLAY CORPORATION

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Charanjit Aulakh's allowance rate?

80.8% of resolved applications examined by Charanjit Aulakh were allowed (1,798 resolved cases), compared with 46.7% across Art Unit 1621 over the last five years.

Does an interview help with examiner Charanjit Aulakh?

This examiner's interview lift is -14.4 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Charanjit Aulakh take to allow a patent?

Applications allowed by Charanjit Aulakh took 755 days on average from filing to allowance.

Which art unit does examiner Charanjit Aulakh work in?

Charanjit Aulakh examines applications in Art Unit 1621 in Tech Center 1600 (Biotechnology & Pharmaceuticals).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month